Adult Dosing

Treatment of cyclic heavy menstrual bleeding

• 1300 mg PO tid x 5 days during monthly menstruation. Max: 5 days

Pediatric Dosing

Treatment of cyclic heavy menstrual bleeding

• Safety and effectiveness in pediatric patients <18 yrs have not been established

[Outline]

• Adult Dosing
• Pediatric Dosing

• Cyclic heavy menstrual bleeding

• Hypersensitivity to any of the ingredient of the product
• Active thromboembolic disease
• History of thrombosis or thromboembolism
• Intrinsic risk of thrombosis or thromboembolism

• N/A

Renal Dose Adjustment (Based on Serum Cr)

• 1.4-2.8 mg/dL: 1300 mg bid x 5 days
• 2.8-5.7 mg/dL: 1300 mg PO daily x 5 days
• >5.7 mg/dL: 650 mg PO daily x 5 days

Hepatic Dose Adjustment

• Hepatic impairment: Dose adjustments not defined

• Anaphylactic shock and severe allergic reactions have been reported
• Concomitant therapy with hormonal contraceptives may further increase the risk of blood clots, stroke, or myocardial infarction hence women using hormonal contraception should use tranexamic acid only if there is a strong medical need and the benefit of treatment will outweigh the potential increased risk of a thrombotic event
• Arterial and venous retinal occlusion has been reported. Discontinuation may be warranted.
• Immediately discontinue use if visual or ocular symptoms occur
• Discontinue the treatment in case of severe allergic reaction
• Tranexamic acid should not be administered concomitantly with Factor IX Complex concentrates or Anti-inhibitor coagulant concentrates as the risk of thrombosis may be increased
• Cerebral edema and cerebral infarction may be caused by use of tranexamic acid in women with subarachnoid hemorrhage

Cautions: Use cautiously in

• Renal impairment
• Concomitant therapy with all- trans retinoic acid in acute promyelocytic leukemia

Pregnancy Category:B

Breastfeeding: Safety unknown, tranexamic acid is present in the mother’s milk at a concentration of about one hundredth of the corresponding serum concentrations hence used during lactation only if clearly needed. Manufacturer advises caution.

• CNS: Headache, migraine, fatigue
• GI: Abdominal pain
• EENT: Sinus, impaired color vision & visual disturbance
• MUSC: Back pain, musculoskeletal pain, arthralgia, muscle cramps & spasm
• HEMA: Anemia
• MISC: Fatigue, severe allergic reaction

• Antifibrinolytic Agents; inhibits the binding and dissolution of hemostatic fibrin by plasmin thereby preserving and stabilizing fibrin’s matrix structure
• Minimally metabolized by liver; CYP450: Unknown
• Renally excreted: >95% (unchanged)
• Half-life: 11 hrs

US Trade Name(s)

• Lysteda

US Availability

tranexamic acid (generic)

• TABS: 650 mg

Lysteda

• TABS: 650 mg

Canadian Trade Name(s)

• Cyklokapron

Canadian Availability

Cyklokapron

• TABS: 500 mg

UK Trade Name(s)

• Cyklokapron

UK Availability

tranexamic acid (generic)

• TABS: 500 mg

Cyklokapron

• TABS: 500 mg

Australian Trade Name(s)

• Cyklokapron

Australian Availability

Cyklokapron

• TABS: 500 mg

[Outline]

Obstetrics/Gynecology

Antifibrinolytics

Pricing data from www.DrugStore.com in U.S.A.

• Lysteda 650 MG TABS [Bottle] (FERRING)
  30 mg = $170
  90 mg = $475.96

Warning: This pricing information is subject to change at the sole discretion of DS Pharmacy. For the most current and up-to-date pricing information, please visit drugstore.com.

Drug Name: Lysteda 650 MG Oral Tablet

Ingredient(s): Tranexamic Acid

Imprint: XP650

Color(s): White

Shape: Oval

Size (mm): 17.00

Score: 1

Inactive Ingredient(s): cellulose, microcrystalline / silicon dioxide / starch, corn / povidone / hypromellose / stearic acid / magnesium stearate

Drug Label Author:
Xanodyne Pharmaceuticals, Inc.

DEA Schedule:
Non-Scheduled